Revolutionizing Biopharma Research: PolyModels Hub’s ModelFlow Cuts Experimentation Time by 90% with €7.9 Million Funding

PolyModels Hub, a London-based startup specializing in the digital transformation of biopharma process development, has successfully secured €7.9 million (£7 million) in a Series A funding round. The funding will be utilized to expand the company’s engineering and product teams, enhance its core platform, and extend its reach to pharmaceutical organizations worldwide.

The funding round was spearheaded by Molten Ventures, with additional participation from Marathon Venture Capital.

CEO and co-founder of PolyModels Hub, Antonio Benedetti, expressed excitement about the digital transformation taking place in the pharmaceutical industry. He highlighted the significant value delivered by the company’s technology and team within a short span of 18 months, leading to global collaborations.

The investment in PolyModels Hub aligns with the 2025 trend of increasing funding for digital and BioTech software solutions. Other companies in the sector, such as ScienceMachine, Kiin Bio, Cellcolabs, and EnsiliTech, have also received substantial investments, indicating a growing interest in the convergence of digital innovation and the life sciences industry in Europe.

PolyModels Hub’s funding round underscores the rising demand for scalable, data-driven infrastructure in biopharma research and development and manufacturing. The company is dedicated to empowering scientists with model-based solutions to advance the development of medicines in the 21st century.

Founded in 2023, PolyModels Hub specializes in BioTech software development for biopharma process development. Its flagship platform, ModelFlow, integrates data, models, and workflows to facilitate the design, simulation, and optimization of pharmaceutical processes.

According to the company, the development of a new drug typically incurs significant costs, with a substantial portion allocated to process development. By streamlining the process through advanced modeling, simulation, and workflow management, PolyModels Hub aims to accelerate drug development, making it more efficient and reproducible.

Molten Ventures CEO, Ben Wilkinson, commended PolyModels Hub for addressing critical challenges in the pharmaceutical industry through a blend of expertise and cutting-edge technology. The company’s rapid adoption and impact across the industry reflect its transformative potential.

The deployment of ModelFlow has shown promising results, reducing experimental workloads significantly while enhancing scientific robustness. This shift towards data-driven infrastructure underscores the strategic importance of process development in pharmaceutical manufacturing.

Marathon Venture Capital Partner, Alex Alexakis, emphasized the importance of embracing data and automation in redefining drug development processes. PolyModels Hub’s innovative approach aims to expedite the delivery of life-changing medicines to patients by modernizing industry practices.

In conclusion, PolyModels Hub’s successful funding round signifies a pivotal moment in the digital transformation of the biopharma industry. With a focus on innovation and efficiency, the company is poised to lead the way in revolutionizing drug development processes for the benefit of patients worldwide.